STAAR Surgical Company (SR3.F)
| Previous close | 37.83 |
| Open | 38.89 |
| Bid | 38.11 x 34300 |
| Ask | 38.36 x 33000 |
| Day's range | 38.89 - 38.89 |
| 52-week range | 25.60 - 51.86 |
| Volume | |
| Avg. volume | 18 |
| Market cap | 1.911B |
| Beta (5Y monthly) | 0.65 |
| PE ratio (TTM) | 134.10 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
STAAR Surgical to Participate in Goldman Sachs 45th Annual Global Healthcare Conference
LAKE FOREST, Calif., June 05, 2024--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, invites investors and the general public to listen to a webcast fireside chat with Patrick F. Williams, Chief Financial Officer, at the upcoming Goldman Sachs 45th Annual Global Healthcare Conference, which will be held in Miami, Florida.
- Business Wire
STAAR Surgical Reports First Quarter 2024 Results
LAKE FOREST, Calif., May 07, 2024--STAAR Surgical Company (NASDAQ: K), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today reported financial results for the first quarter ended March 29, 2024.
- Business Wire
STAAR Surgical Announces Milestone Strategic Agreement in U.S. with IQ Laser Vision
LAKE FOREST, Calif., May 07, 2024--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announces another milestone achieved on its U.S. Highway 93 go-to-market program – a strategic agreement with IQ Laser Vision, a leader in providing clear vision to clients with locations across California and Texas, and a top EVO ICL practice in North America.
